Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10Plasma cell 6Genitourinary 6Gastrointestinal 4Thoracic 3Head & Neck 2Tumor-Agnostic 1Sarcoma 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Denosumab × Dermatologic × Clear all
NCT03620019 2026-03-27

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
25 enrolled 16 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡